Company profile for Toragen

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Toragen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers. Our team is comprised of industry leaders with decades of experience in early stage biotechnology startups, translational drug development, and practice-changing Phase III clinical trials. oragen is preparing to initiate a Phase I clinical trial with its lead compound in HPV-associated malignancies and i...
Toragen is focused on repurposing anti-viral drugs and developing novel immunotherapies to treat viral-associated cancers. Our team is comprised of industry leaders with decades of experience in early stage biotechnology startups, translational drug development, and practice-changing Phase III clinical trials. oragen is preparing to initiate a Phase I clinical trial with its lead compound in HPV-associated malignancies and is seeking investor funding for research and development.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
10210 Campus Point Dr, Ste 150, San Diego, California 92121
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20251029010827/en/Toragen-Inc.-Receives-Grant-to-Conduct-Studies-to-Explore-Application-of-TGN-S15-for-Premalignant-Lesions-at-Earliest-Stages

BUSINESSWIRE
29 Oct 2025

https://www.businesswire.com/news/home/20250930075876/en/Toragen-Inc.-Announces-%2412-Million-Convertible-Note-Financing-and-Expansion-of-Board-of-Directors

BUSINESSWIRE
30 Sep 2025

https://www.businesswire.com/news/home/20250415547251/en/Toragen-Inc.-Provides-Update-on-Phase-1-Clinical-Trial-of-TGN-S11-as-Monotherapy-and-in-Combination-with-Keytruda-in-Patients-with-Stage-4-HPV-Associated-Cancers

BUSINESSWIRE
15 Apr 2025

https://www.businesswire.com/news/home/20241118080529/en

BUSINESSWIRE
18 Nov 2024

https://www.businesswire.com/news/home/20231212958282/en

BUSINESSWIRE
12 Dec 2023

https://www.businesswire.com/news/home/20231106195653/en

BUSINESSWIRE
06 Nov 2023

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty